NewsKRM Ayurveda Schedules FY26 Investor Presentation; Reports ₹10,169.07 Lakh Revenue with 32.84% YoY GrowthKRM Ayurveda Schedules FY26 Investor Presentation; Reports ₹10,169.07 Lakh Revenue with 32.84% YoY Growth
KRM Ayurveda Limited filed an investor presentation under Regulation 30 of SEBI (LODR) Regulations, 2015, for a conference call scheduled on May 05, 2026, covering H2 and full-year FY26 results. The company reported FY26 revenue from operations of ₹10,169.07 Lakh (up 32.84% YoY), EBITDA of ₹3,112.02 Lakh at a 30.60% margin, and PAT of ₹2,012 Lakh at a 19.79% margin. H2 FY26 performance was notably strong, with EBITDA growing 102.14% YoY and PAT rising 148.84% YoY. The company operates 6 hospitals and 8 clinics with a total bed capacity of 223 and a 69% bed occupancy rate as per FY 2026 data.
*this image is generated using AI for illustrative purposes only.
KRM Ayurveda Limited has filed an investor presentation with the National Stock Exchange of India under Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation, covering the company's H2 and full-year financial performance for FY 2025-26, is being used during a Group Conference Call with investors scheduled for Tuesday, May 05, 2026. The filing was signed by Sanchit Hans, Whole-Time Director (DIN: 09228549), on May 04, 2026.
FY26 and H2 FY26 Financial Highlights
KRM Ayurveda delivered strong financial results for FY26, with revenue from operations crossing ₹10,169.07 Lakh, representing 32.84% YoY growth. EBITDA and PAT both expanded significantly, reflecting improved operating leverage across the company's integrated healthcare model. H2 FY26 results were especially notable, with EBITDA more than doubling on a year-on-year basis.
The table below summarises the key financial metrics for FY26 and H2 FY26:
| Metric: | FY26 | YoY Growth | H2 FY26 | YoY Growth |
|---|---|---|---|---|
| Revenue from Operations: | ₹10,169.07 Lakh | 32.84% | ₹5,333.36 Lakh | 30.59% |
| EBITDA: | ₹3,112.02 Lakh | 62.59% | ₹1,787.11 Lakh | 102.14% |
| EBITDA Margin: | 30.60% | — | 33.51% | — |
| PAT: | ₹2,012 Lakh | 79.42% | ₹1,189.73 Lakh | 148.84% |
| PAT Margin: | 19.79% | — | 22.31% | — |
Comparative figures are for H2 FY25 and FY25 respectively.
Management Commentary
Dr. Puneet Dhawan, Managing Director & Promoter, commented on the results: "Our FY26 performance marks a transformational year for KRM Ayurveda as we crossed the ₹10,169.07 Lakhs Revenue from operations milestone in FY26, while H2 FY26 EBITDA surged ~102% YoY and PAT grew ~149% YoY, reflecting the strength of our integrated healthcare model and disciplined execution. Our strategic focus on expanding hospitals, specialty care, and digital health is driving stronger margins, improving revenue quality, and deepening consumer trust. Backed by a strengthened post-IPO balance sheet, we are well-positioned to accelerate growth across India and global markets through digital healthcare, medical tourism, and innovation-led Ayurveda solutions."
Business Overview and Operational Metrics
KRM Ayurveda was established in 2019 and has grown from a kidney-specialty hospital to a multi-specialty Ayurvedic healthcare network. As per FY 2026 data, the company operates across the following key parameters:
| Parameter: | Details |
|---|---|
| Hospitals: | 6 |
| Clinics: | 8 |
| Total Bed Capacity: | 223 |
| Bed Occupancy: | 69% |
| ARPOB: | ~₹8,400 |
| Employees: | 430+ |
| YouTube Subscribers: | 8 lakh+ (across 3 channels) |
| PAT Margin: | 19.8% |
| ROCE: | 26% |
| Return on Equity: | 29% |
| Return on Fixed Assets: | 76% |
The company's hospital network spans Delhi (30 beds), Gurgaon (95 beds), Jaipur — two facilities (20 and 30 beds), Udaipur (30 beds), and Lucknow (18 beds). Specialty clinics are located in Bengaluru, Patna, Mumbai, Lucknow, and Noida. The clinical team comprises 40+ qualified Ayurvedic physicians (BAMS) and 71+ certified therapists.
Revenue Mix and Business Model
KRM Ayurveda operates a dual revenue stream model encompassing the sale of products and services. The revenue bifurcation has shifted meaningfully over recent fiscal years, reflecting the growing contribution of hospital and clinic services:
| Fiscal Year: | Sale of Products | Sale of Services |
|---|---|---|
| FY 2023: | 93.4% | 6.6% |
| FY 2024: | 90.3% | 9.7% |
| FY 2025: | 64.3% | 35.7% |
| FY 2026: | 46.2% | 53.8% |
The company's manufacturing operations are conducted at a GMP and ISO-certified production facility in Kundli, Haryana, producing classical and proprietary Ayurvedic formulations in the form of capsules, tablets, syrups, and oils. Products address therapeutic areas including kidney and liver health, digestive care, skin wellness, and stress and lifestyle management.
Market Context and Strategic Priorities
The Indian AYUSH sector was valued at $43 billion in 2024, having grown from $18 billion in 2020, with government budgetary allocation rising from ₹153 billion in FY15 to ₹461.3 billion in FY26. The sector's composition in India comprises 53.69% manufacturing and 46.31% services, with the number of registered practitioners reaching 7,51,768 in 2025 and AYUSH colleges numbering 1,137 as of 2024.
KRM Ayurveda's stated strategic priorities include:
- Digital Health Expansion: Scaling a 500-seat telemedicine marketing team with AI-driven patient management systems
- Geographic Expansion: Targeting tier II cities in India and telemedicine outreach into the USA
- Medical Tourism: Developing wellness packages for international patients
- Therapist Training: Accredited by Rashtriya Ayurveda Vidyapeeth (RAV) to conduct certified Ayurveda training programs, with the first batch completed in FY 2024-25
- Product Portfolio Expansion: Introduction of new wellness product lines and wider distribution network development
The investor presentation is also available on the company's website at www.krmayurveda.com .
Historical Stock Returns for KRM Ayurveda
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.63% | +11.07% | +34.79% | +40.98% | +40.98% | +40.98% |
How does KRM Ayurveda plan to finance its geographic expansion into tier II cities and the US telemedicine market without diluting its post-IPO balance sheet strength?
Given the rapid shift from product-led to service-led revenue, what risks does KRM Ayurveda face in maintaining its current 69% bed occupancy rate as it scales hospital capacity?
With the AYUSH sector attracting increasing competition from larger healthcare conglomerates, how sustainable is KRM Ayurveda's premium EBITDA margin of ~30% over the next 2-3 years?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
